Related Experiment Video
Updated: Mar 25, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Prostate Cancer Imaging with Novel PET Tracers
Liza Lindenberg1,2, Peter Choyke3,4, William Dahut5,6
1Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. liza.lindenberg@mail.nih.gov.
Abstract:
Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.
Insights
Researchers are developing new molecular imaging agents to improve prostate cancer detection and treatment. These novel radiotracers show promise for advancing diagnostics and enabling theranostic applications for this malignancy.
Area of Science:
- Nuclear medicine
- Oncology
- Molecular imaging
Background:
- Current molecular imaging techniques for prostate cancer have limitations.
- Prostate cancer heterogeneity presents challenges for radiotracer development.
- Novel agents are needed to enhance tumor targeting and detection accuracy.
Purpose of the Study:
- To review emerging nuclear medicine tracers for prostate cancer.
- To highlight innovative radiotracers targeting various prostate cancer mechanisms.
- To discuss the potential of these tracers for diagnostics and theranostics.
Main Methods:
- Review of nuclear medicine tracers targeting specific prostate cancer pathways.
- Focus on agents for bone metastasis, cell membrane synthesis, amino acid analogs, androgen analogs, and prostate specific membrane antigen (PSMA).
Main Results:
- Several innovative radiotracer compounds demonstrate encouraging results.
- Advancements in diagnostic accuracy for prostate cancer are anticipated.
- New opportunities for theranostic applications are emerging.
Conclusions:
- Novel radiotracers are significantly advancing prostate cancer molecular imaging.
- These agents offer improved diagnostic capabilities.
- The development holds promise for future theranostic applications in prostate cancer management.
More Related Videos
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...